ERBB2 and gastric cancer: We also demonstrated that combination treatment of HER2-expressing gastric cancer cells with trastuzumab and pertuzumab additively enhanced CD137 expression in NK cells, followed by confirmation that CD137 stimulation using rhCD137L enhanced NK cell cytotoxicity toward mAb-coated tumor cells.